

# Publication of Annual Report

RNS Number : 3885S

Novacyt S.A.

14 June 2024

NOVACYT

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

## Publication of Annual Report

**Paris, France, and Eastleigh and Manchester, UK - 14 June 2024** - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that the Company's Annual Report and Accounts ("Annual Report") for the year ended 31 December 2023 has been published and uploaded to the Company's website. The Annual Report will be posted to all shareholders that hold ordinary shares through CREST Depository Interests (CDIs).

## Contacts

**Novacyt SA** <https://novacyt.com/investors>

Lyn Rees, Chief Executive Officer

**Via Walbrook PR**

Steve Gibson, Chief Financial Officer

**SP Angel Corporate Finance LLP (Nominated Adviser and Broker)** +44 (0)20 3470 0470

Matthew Johnson / Charlie Bouverat (Corporate Finance)  
Vadim Alexandre / Rob Rees (Corporate Broking)

**Deutsche Numis (Joint Broker)**

+44 (0)20 7260 1000

Freddie Barnfield / Duncan Monteith / Michael Palser

**Allegra Finance (French Listing Sponsor)**  
Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10 r.durgetto@allegrafinance.com /  
y.petit@allegrafinance.com

---

**Walbrook PR (Financial PR & IR)**  
Stephanie Cuthbert / Paul McManus /  
Phillip Marriage / Alice Woodings

+44 (0)20 7933 8780 or novacyt@walbrookpr.com  
+44 (0)7796 794 663 / +44 (0)7980 541 893  
+44 (0)7867 984 082 / +44 (0)7407 804 654

---

### **About Novacyt Group** ([www.novacyt.com](http://www.novacyt.com))

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

---

#### **Clinical**

Broad portfolio of human clinical *in vitro* diagnostic products, workflows and services focused on three therapeutic areas:

- Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
  - Precision Medicine: DPYD genotyping assay
  - Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel
- 

#### **Instrumentation**

Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:

- Ranger® Technology: automated DNA sample preparation and target enrichment technology
  - MyGo: real-time quantitative PCR (qPCR) instruments
- 

#### **Research Use Only**

Range of services for the life sciences industry:

- Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
  - Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)
- 

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: [www.novacyt.com](http://www.novacyt.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com). RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ACSFJMFTMTMBBAI